GE Healthcare recently announced numerous recently finalized agreements in various areas of its business. They include;
- A multi-year strategic agreement with United Pharmacy Partners, Inc (UPPI). The result of this contract is that GE will provide positron emission tomography (PET) radiopharmacy technology, including PETtrace cyclotron and TRACERlabPET chemistry platform used for the production of PET radiopharmaceuticals, to UPPI members across the United States;
- GE Healthcare and Ethicon Endo-Surgery Inc. announced a collaborative sales and marketing agreement to help launch a new solution designed to reduce the number of open surgical breast biopsies performed each year. The parties to this agreement will promote two technologies working in tandem: the Ethicon Endo-Surgery advanced Mammotome EX Biopsy System and the GE LOGIQ Book XP compact ultrasound system;
- A study by GE in collaboration with Roche is aimed at developing personalized care for patients with Alzheimer's disease. In controlled clinical trials, patients taking a Roche anti-amyloid drug candidate for Alzheimer's will be monitored clinically for drug response using GE's positron emission tomography (PET) diagnostic imaging agent. This proprietary PET technology measures and tracks levels of beta-amyloid, a form of brain plaque believed to cause memory loss in Alzheimer's patients. Previously, the presence of plaque can only be confirmed on autopsy. In this study, both Roche and GE will independently analyze patient data to monitor the progression of the disease and then share information to validate the efficacy of both the therapeutic product and the diagnostic tool. The data gathered will aid both companies in submitting necessary and comprehensive data to regulatory authorities for approval.